SUPPRESSION BY THE SUMATRIPTAN ANALOG, CP-122,288 OF C-FOS IMMUNOREACTIVITY IN TRIGEMINAL NUCLEUS CAUDALIS INDUCED BY INTRACISTERNAL CAPSAICIN

1 The effects of an intravenously administered sumatriptan analogue we re examined on c-fos-like immunoreactivity (c-fos-LI), a marker of neu ronal activation, evoked within trigeminal nucleus caudalis (TNC) and other brain stem regions 2 h after intracisternal injection of the irr itant, capsaicin (0.1 mi, 0.1 mM), in pentobarbitone-anaesthetized Har tley guinea-pigs. 2 C-fos-LI was assessed in eighteen serial sections (50 mu m) using a polyclonal antiserum. A weighted average, reflecting total expression within lamina I, II0 of TNC was obtained from three representative levels (i.e., at -0.225 mm, -2.475 mm and -6.975 mm.) 3 Capsaicin caused significant labelling within lamina I, II0, a region containing axonal terminations of small unmyelinated C-fibres, as wel l as within the nucleus of the solitary tract, area postrema and media l reticular nucleus. A similar distribution of positive cells was repo rted previously after intracisternal injection of other chemical irrit ants such as autologous blood or carrageenin. 4 Pretreatment with a co nformationally restricted sumatriptan analogue (with some selectivity for 5-HT1B and 5-HT1D receptor subtypes) CP-122,288, reduced the weigh ted average by approximately 50-60% (P<0.05) in lamina I, II0 at great er than or equal to 100 pmol kg(-1), i.v., but did not decrease cell n umber within area postrema, nucleus of the solitary tract or medial re ticular nucleus. A similar pattern was reported previously following s umatriptan, dihydroergotamine or CP-93,129 administration after noxiou s meningeal stimulation. 5 We conclude that modifications at the amino -ethyl side chain of sumatriptan dramatically enhance the suppression of c-fos expression within TNC, a finding consistent with its remarkab le potency against neurogenic plasma protein extravasation within dura mater. CP-122,288 and related analogues may serve as an important pro totype for drug development in migraine and related headaches.